MOLECULAR INSIGHT PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1997-01-01
- Employees
- 71
- Market Cap
- -
- Website
- http://molecularinsight.com
Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
- Conditions
- ParagangliomaPheochromocytoma
- First Posted Date
- 2009-06-02
- Last Posted Date
- 2013-06-10
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00911729
- Locations
- 🇺🇸
Oxford Outcomes- Nationwide Recruitment within the US, Bethesda, Maryland, United States
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
- Conditions
- PheochromocytomaParaganglioma
- Interventions
- Radiation: Ultratrace® Iobenguane I131
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT00874614
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
🇺🇸University of California-San Francisco, San Francisco, California, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma
- Conditions
- Metastatic Melanoma
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00747825
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00712829
- Locations
- 🇺🇸
Johns Hopkins Medical Institutes - Neuroradiology Division, Baltimore, Maryland, United States
🇺🇸New York Weill Cornell Medical Center - New York Presbyterian Hospital, New York, New York, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
- Conditions
- Malignant Carcinoid Tumor
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Registration Number
- NCT00696930
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00659984
- Locations
- 🇺🇸
Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸University of Chicago Comer Children's Hospital, Chicago, Illinois, United States
Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT00514501
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
- Conditions
- PheochromocytomaParaganglioma
- Interventions
- Drug: Ultratrace Iobenguane (MIBG) I 131
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00458952
- Locations
- 🇺🇸
New York Presbyterian Hospital-Weill Cornell Medical Center, New York, New York, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Rhode Island Hospital, Providence, Rhode Island, United States
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
- Conditions
- PheochromocytomaParagangliomaCarcinoid
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00339131